IP Library › Granted Patent US 12,295,999
Granted Patent B2
US 12,295,999 · App. 18/453,684 · Granted May 13, 2025

Vaccine for protection against

Inventor: Antonius Arnoldus Christiaan Jacobs (Kessel, NL)
Assignee: Intervet Inc.
A61K39/092A61K2039/545A61K2039/552C12N9/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,295,999
App. No.
18/453,684
Granted
May 13, 2025
Kind
B2
Abstract

The present invention pertains to a vaccine comprising an immunologically effective amount of an IgM protease antigen of Streptococcus suis , for use in a method for protecting pigs against a pathogenic infection with Streptococcus suis by administering the vaccine only once, wherein the vaccine comprises at most 120 μg per dose of the antigen.

Claims (6)

1. A method for protecting a pig against a pathogenic infection with Streptococcus suis by administering a vaccine comprising an immunologically effective amount of an IgM protease antigen of Streptococcus suis only once to the pig, wherein the vaccine comprises at most 120 μg of the antigen per dose.

2. The method of claim 1 , wherein the administering of the vaccine to the pig is performed when the pig is at an age of at most 28 days.

3. The method of claim 1 , wherein the administering of the vaccine to the pig is performed before the pig is at an age at which the pig is weaned.

4. The method of claim 1 , wherein the pig has maternally derived anti- Streptococcus suis antibodies.

5. The method of claim 1 , wherein the method of administering of the vaccine to the pig is for conferring protection against mortality associated with a pathogenic infection with Streptococcus suis.

6. The method of claim 1 , wherein the method of administering of the vaccine to the pig is for conferring protection against clinical signs associated with a pathogenic infection with Streptococcus suis.

Assignments (2)
CHANGE OF ADDRESS Recorded Sep 26, 2023
From: INTERVET INC.
To: INTERVET INC.
Reel/Frame 065028/0818 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2023
From: JACOBS, ANTONIUS ARNOLDUS CHRISTIAAN
To: INTERVET INC.
Reel/Frame 064667/0064 →
Continuity (3)
Continuation 16766977 · May 26, 2020
Continuation PCTEP2018084884 · Dec 14, 2018
Related Publication 20230390376A1 · Dec 7, 2023
References Cited (22)
US 10751403B2 · Jacobs · 2020 [cited by examiner]
US 11103569B2 · Jacobs · 2021 [cited by examiner]
US 11167021B2 · Jacobs · 2021 [cited by examiner]
JP 2017518367A · 2017 [cited by applicant]
WO WO2015181356A1 · 2015 [cited by applicant]
WO WO2017005913A1 · 2017 [cited by applicant]
WO WO2017134274A1 · 2017 [cited by applicant]
WO WO2019115741A1 · 2019 [cited by applicant]
European Patent Office, European Search Report dated Apr. 11, 2018 for European Patent Application No. 17207758.8 (6 pages). [cited by applicant]
Iveson et al., 2016, “Health and welfare of pigs before and after weaning,” Vet Times, Jul. 18, 2016 (7 pages). [cited by applicant]
Seele et al., 2015, “The immunoglobulin M-degrading enzyme of [cited by applicant]
Segura, 2015, “ [cited by applicant]
Notice of Opposition filed by Intervet International B.V. on Jul. 27, 2021 against European Patent No. EP3148576B1 (10 pages). [cited by applicant]
Declaration of Antonius Arnoldus Christiaan Jacobs dated Jun. 17, 2021 filed in Opposition against European Patent No. EP3148576B1 by Intervet International B.V. on Jul. 27, 2021 as D3 (4 pages). [cited by applicant]
Reply to the summons to attend oral proceedings dated Apr. 13, 2022 filed by Intervet International B.V. on Aug. 4, 2022 in Opposition against European Patent No. EP3148576B1 (12 pages). [cited by applicant]
Grommen et al., 2022, Efficacy of an experimental [cited by applicant]
European Patent Office, Communication pursuant to Rule 114(2) EPC dated Nov. 10, 2022 regarding transmittal of third party observations filed by Plasseraud IP on Nov. 4, 2022 in European Patent Application No. 18829275.… [cited by applicant]
Baums et al., 2010, “Immunogenicity of an autogenous [cited by applicant]
Hsueh et al., 2017, “Immunization with [cited by applicant]
Lapointe et al., 2002, “Antibody response to an autogenous vaccine and serologic profile for [cited by applicant]
Seele et al., 2013, “Identification of a novel host-specific IgM protease in [cited by applicant]
Wisselink et al., 2002, “Assessment of protective efficacy of live and killed vaccines based on a non-encapsulated mutant of [cited by applicant]